Impact of non-pharmaceutical interventions on documented cases of COVID-19

Author:

Banholzer NicolasORCID,van Weenen Eva,Kratzwald Bernhard,Seeliger Arne,Tschernutter DanielORCID,Bottrighi Pierluigi,Cenedese Alberto,Salles Joan Puig,Vach WernerORCID,Feuerriegel StefanORCID

Abstract

AbstractBackgroundThe novel coronavirus (SARS-CoV-2) has rapidly evolved into a global epidemic. To control its spread, countries have implemented non-pharmaceutical interventions (NPIs), such as school or border closures, while others have even enforced complete lockdowns. Here we study the impact of NPIs in reducing documented cases of COVID-19. Documented case numbers are selected because they are essential for decision-makers in the area of health-policy when monitoring and evaluating current control mechanisms.MethodsWe empirically estimate the relative reduction in the number of new cases attributed to each NPI. A cross-country analysis is performed using documented cases through April 15, 2020 from n = 20 countries (i.e., the United States, Canada, Australia, the EU-15 countries, Norway, and Switzerland).ResultsAs of April 15, venue closures were associated with a reduction in the number of new cases by 36 % (95% credible interval [CrI] 20–48 %), closely followed by gathering bans (34 %; 95% CrI 21–45 %), border closures (31 %; 95% CrI 19–42 %), and work bans on non-essential business activities (31 %; 95% CrI 16–44 %). Event bans lead to a slightly less pronounced reduction (23 %; 95% CrI 8–35 %). School closures (8 %; 95% CrI 0–23 %) and lockdowns (5 %; 95% CrI 0–14 %) appeared to be the least effective among the NPIs considered in this analysis.ConclusionsWith this cross-country analysis, we provide early estimates regarding the impact of different NPIs for controlling the COVID-19 epidemic. These findings are relevant for evaluating current health-policies.

Publisher

Cold Spring Harbor Laboratory

Reference23 articles.

1. WHO. Coronavirus disease 2019 (COVID-19): Situation Report 91; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200420-sitrep-91-covid-19.pdf?sfvrsn=fcf0670b_4.

2. Guan W , Ni Zy , Hu Y , Liang Wh , Ou Cq , He Jx , et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020 2;.

3. Li Q , Guan X , Wu P , Wang X , Zhou L , Tong Y , et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020;.

4. Wu F , Zhao S , Yu B , Chen YM , Wang W , Song ZG , et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;.

5. Zhou P , Yang XL , Wang XG , Hu B , Zhang L , Zhang W , et al. Apneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;.

Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3